Worldwide reach for clinical trial supply services UK and Europe: Global clinical trial supply services tailored for you! Strategic Sourcing – ClientPharma’s ethos is to challenge the norms and adapt to your specific needs. We understand the difficulties of multi-faceted projects with time and temperature delivery requirements. Biosimilars & Reference Medicines – ClientPharma’s clinical trial Project Management team brings proficiency in management and mitigation of risks. You can say goodbye to issues and delays and hello to peace-of-mind. See more information on clinical research commercial drug supply.
We profoundly understand and recognize the numerous risks associated with global drug procurement. We also appreciate the many complexities associated with worldwide storage and distribution of clinical trial supplies. Our team knows the importance of an efficient, robust supply chain — audited & approved — that promotes excellence, security and accountability. We provide batch traceability, supporting documentation (i.e. Certificates of Analysis (CofAs), Batch Release Certificates (BRCs), GMP Statements, stability data, Fit-for-Use (FFU) Statements, Certificates of Conformance (CofCs), Certificates of Origin (CofOs), etc.) and temperature monitoring data – delivering product pedigree and authenticity.
Supplying the world’s most respected biopharmaceutical companies – ClientPharma handles the numerous challenges of obtaining medicines quickly, in multiple lots, with ranging expiry dating – and we can source and supply from any region in the world! Our deep understanding and skill gives you the visibility needed to fulfill your clinical trial project requirements: Proactive market research and insights Procurement planning services; Worldwide sourcing capabilities; Collection and collation of multiple batches; Provision of batch documentation; Extensive experience and knowledge of emerging markets.
Our temperature-controlled capabilities include 2°- 8°C and 15°- 25°C facilities, as well as access to specialist transport to manage deliveries around the world according to product temperature requirements. Extensive capabilities: Our capabilities include stock receipt, import & export expertise, in-territory regulatory specialists, product reconciliation and destruction services. You can trust us: Our highly trained logistics team is dedicated to providing a robust clinical trial supply chain and trusted product integrity with regulatory compliant distribution through validated temperature-controlled logistics. We provide the peace-of-mind you need, offering you with dedicated clinical trial supply chain solutions to meet the explicit needs of your clinical programs. See extra details on https://www.clientpharma.com/.
ClientPharma (CP), a global clinical trial supply company, specializing in the procurement of commercial drug for clinical research, announced today it has formed a strategic partnership with TrialCard, a full-service life sciences commercialization partner. As a result, global clinical supply and operations teams can now single source their commercial drug requirements by utilizing two best-in-class solution providers. TrialCard Incorporated is a full-service life sciences commercialization partner that provides comprehensive solutions that span the entire biopharmaceutical value chain. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. Founded in 2000, TrialCard provides commercialization needs for more than 160 life science customers and has connected over 35 million patients with more than $18 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina.
Supply and demand of pharmaceuticals are mutually exclusive. The supply chain is wholly reliant upon pharmaceutical companies being able to effectively forecast demand for a particular product. The process of forecasting is often made difficult when a new medicine has just been brought to market or rapid deployment of a drug needs to happen in response to a pandemic due to a lack of concrete evidence to base estimations on. In a survey of pharmaceutical Senior Managers it was reported that the majority of pharmaceutical companies had miscalculated demand for new medicines by up to 25%. Michael Lehmann, executive vice president of sales and marketing for Patheon, a global provider of outsourced pharmaceutical development and manufacturing said, “Making accurate demand forecasts is extremely challenging for pharmaceutical companies”.
